Molecular typing detection system based on third-generation sequencing and kit thereof

Through third-generation sequencing technology and ONT's PromethION nanopore sequencing, the problem that second-generation sequencing is difficult to detect other SVs in leukemia except for common gene rearrangements is solved, and more efficient and accurate leukemia molecular typing is achieved, especially for B -ALL's "B-other" subtype provides wider detection coverage and higher identification accuracy.

CN118910236APending Publication Date: 2024-11-08RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202410950833.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-16
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing second-generation sequencing technologies are difficult to accurately detect other structural variants (SVs) in leukemia except for common gene rearrangements, resulting in high false negative and false positive rates, and cannot fully cover all potential SVs, especially for B-ALL. Patients with "B-other" subtype lack effective molecular typing methods.

Method used

Using a molecular typing detection system and kit based on third-generation sequencing, ONT's PromethION nanopore sequencing technology can read more than 10,000 bases of DNA fragments at one time, and detect SV in leukemia cells through long-read sequencing technology. Combined with DNA extraction kits and data analysis units, provide more accurate molecular typing results.

Benefits of technology

Achieved molecular typing with high detection throughput, fast speed and wide coverage, and more accurately identified SV in leukemia cells, making up for the shortcomings of second-generation sequencing technology and improving the identification accuracy of B-ALL subtypes. , especially for the "B-other" subtypes that are difficult to classify, provide new detection methods.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118910236A_ABST
    Figure CN118910236A_ABST
Patent Text Reader

Abstract

The invention relates to a molecular typing detection system based on third-generation sequencing and a kit thereof. The detection system and the kit thereof are high in detection flux, high in speed, wide in coverage and more accurate in SV identification, and have a good market application prospect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of leukemia detection, and in particular relates to a molecular typing detection system based on third-generation sequencing and a kit thereof. Background Art

[0002] Acute lymphoblastic leukemia (ALL) is a blood system malignancy originating from immature lymphocytes in the bone marrow and is the most common malignant tumor among adolescents in my country. Although its cure rate has been significantly improved (reaching more than 80%), it is still one of the important causes of death among adolescents due to disease, and the prognosis of adult ALL patients is still poor - only about 40% of patients achieve long-term complete remission.

[0003] Since Karl Skorecki and Joseph Berman first proposed in 1973 that chromosome 9 and chromosome 22 were translocated to form the BCR-ABL fusion gene, a series of tyrosine kinase inhibitors (TKI) have been developed for this fusion gene, including the first-generation TKI imatinib, the second-generation and third-generation TKI nilatinib, dasatinib, etc., which have significantly improved the survival and prognosis of BCR-ABL patients. At present, the molecular typing method of B-ALL mainly adopts MICM typing, which integrates leukemia cell morphology (morphology, M), immunology (immunology, I), cytogenetics (cytogenetics, C) and molecular biology characteristics (molecular biology, M).

[0004] With the rapid development of sequencing technology, the genetic stratification of B-ALL is currently mainly carried out through second-generation sequencing (also known as short-read sequencing), including the use of RNA-seq to determine the patient's gene rearrangement and WES to screen for common site mutations. In 2018, Shanghai Ruijin Hospital has divided B-ALL into 14 subtypes through large-sample transcriptome sequencing, and identified 6 rare subtypes in addition to the 2016 World Health Organization (WHO) classification, including MEF2D rearrangement and ZNF384 rearrangement. Among them, studies have reported that MEF2D rearrangement is sensitive to histone deacetylase (HDAC) inhibitors; ZNF384 rearrangement is sensitive to FLT3 inhibitors, providing new prospects for molecular classification and targeted treatment. In 2022, WHO updated the B-ALL classification into 9 subtypes, including 3 chromosome number changes: hyperdiploidy, hypodiploidy, iAMP21; 6 fusion gene changes: BCR-ABL1 / Ph-like, KMT2A rearrangement, ETV6-RUNX1 / -like, TCF3-PBX1, IGH-IL3, TCF3-HLF. Nowadays, these molecular classifications have been applied to clinical diagnosis and treatment, and patients are divided into standard risk and high risk according to different genetic events, providing a reference for patients' medication and prognosis assessment.

[0005] It is true that 90% of B-ALL patients have been successfully typed through the above-mentioned second-generation sequencing method, but nearly 10% of patients cannot be typed, and these patients are called "B-other" subtypes. In addition to the fusion genes caused by the above-mentioned chromosome rearrangements, structural variations (SVs) such as gene deletions, inversions, and duplications can also cause the occurrence of diseases. For example, the newly defined IKZF1 PLUS subtype is caused by the deletion of multiple leukemia-related genes, which leads to poor clinical prognosis. Since the second-generation sequencing can only read 500-600bp in length at a time, it is difficult to sequence across the above-mentioned SV breakpoints; at the same time, SVs are often surrounded by repetitive sequences, and short-read sequence data often cannot be clearly mapped back to their correct genomic positions, and de novo assembly technology cannot capture new sequences; in addition, short-read analysis algorithms cannot systematically detect SVs, and the false negative and false positive rates can exceed 50%. Therefore, the use of current second-generation sequencing methods leads to the omission of a large number of SVs, especially other SVs besides the gene rearrangements that are currently being closely watched. This urgently requires new detection methods to make up for the shortcomings of second-generation short-read sequencing.

[0006] Long-read sequencing, also known as third-generation sequencing, has the characteristics of long read length and no need for PCR amplification. It performs one-time raw reading of DNA fragments of more than 10,000 bases. It has been proven in a variety of diseases and models that long-read sequencing can detect more SVs more accurately than short-read sequencing. Among them, PromethION nanopore sequencing by ONT (Oxford Nanopore Technologies) has been proven to be an effective tumor whole genome sequencing analysis method. Its sequencing N50 reaches tens of kb, and tens of thousands of SVs can be detected in tumor samples, and most SVs are not detected by conventional short-read sequencing. In breast cancer cell lines, nanopore sequencing was used to discover a complex KLHDC2-SNTB1 fusion consisting of three independent chromosome regions in breast cancer cell lines (SK-BR-3), which is larger than 10kb. It can be seen that long-read sequencing may provide a new direction for studying tumor SVs. Summary of the invention

[0007] The technical problem to be solved by the present invention is to provide a molecular typing detection system based on third-generation sequencing and a kit thereof, which has high detection throughput, fast speed, wide coverage and more accurate identification of SV.

[0008] The present invention provides a molecular typing detection system based on third-generation sequencing, comprising:

[0009] a) Sample module;

[0010] The sample modules include:

[0011] a1) a sample unit comprising a leukemia cell suspension derived from a subject, wherein the density of the leukemia cells in the suspension is 2×10 7 / ml to 5x10 7 / ml;

[0012] b) at least one detection module, which is used to detect leukemia cells and structural variations present in the subject, so as to perform molecular typing;

[0013] The at least one detection module comprises:

[0014] b1) an extraction unit, which contains reagents that can easily extract DNA to obtain DNA for subsequent detection;

[0015] The reagents include lysis solution, enzyme inhibitors, buffer and distilled water.

[0016] Furthermore, the sample module may include:

[0017] a2) a separation unit, comprising a monocyte separation solution for centrifugally separating the leukemia cells of the subject.

[0018] a3) A T cell depletion unit, which is used to deplete T cells from a sample derived from a subject with non-T cell leukemia, thereby obtaining the leukemia cell suspension.

[0019] Furthermore, the detection module also includes:

[0020] b2) A data analysis unit, which includes a module for analyzing the sequencing results to obtain characteristic gene sequences of the subject's leukemia cells.

[0021] b3) A molecular typing unit, which comprises the characteristic gene sequence of the leukemia cells of the above-mentioned subject, thereby obtaining the SV type of the leukemia cells of the subject.

[0022] The invention provides a molecular typing detection kit based on third-generation sequencing, comprising a DNA extraction reagent; the DNA extraction reagent comprises a lysate, an enzyme inhibitor, a buffer solution and distilled water.

[0023] Preferably, the lysis solution comprises buffer AL, buffer MB, buffer MW1, buffer PE, buffer AE and MagAttract Suspension G.

[0024] Preferably, the enzyme inhibitors include proteinase K and RNase A.

[0025] Preferably, the buffer is PBS buffer.

[0026] Furthermore, the sample DNA is extracted using the DNA extraction reagent and then a library is constructed. After sequencing on a machine, the molecular typing result of leukemia is obtained through data analysis.

[0027] Preferably, the DNA is HMW DNA.

[0028] Preferably, the molecular typing distinguishes B-ALL subtypes.

[0029] Preferably, the sequencing is long-read sequencing.

[0030] The present invention also provides a method for using a third-generation sequencing molecular typing detection kit, comprising the following steps:

[0031] The sample DNA is extracted using a DNA extraction reagent and then a library is constructed. After sequencing on a machine, the SV diagnosis results of leukemia are obtained through data analysis.

[0032] The sample DNA concentration is 50-100 ng / ul.

[0033] Beneficial Effects

[0034] (1) The sample extraction of the kit of the present invention is simple: the patient sample extraction only needs a few hours of processing and can be directly put into the machine for sequencing detection. (2) The detection throughput of the kit of the present invention is high and the speed is fast: ONT long-read sequencing is adopted, which is simpler than second-generation sequencing. ONT's PromethIon instrument can sequence 48 samples at the same time. After 48 hours, one chip can obtain up to 150G of data, which is more efficient than second-generation sequencing.

[0035] (3) The kit of the present invention has a wide coverage: long-read ONT sequencing can sequence the entire genome and comprehensively detect all SVs present in the sample, with a wider coverage. In addition to conventional gene fusions, it can detect other SVs that are easily missed by second-generation sequencing, such as deletions, duplications, inversions, etc., making up for the shortcomings of the current B-ALL molecular typing.

[0036] (4) The kit of the present invention can identify SVs more accurately: the N50 of long-read sequencing can be as long as tens of kb, which avoids the shortcomings of short-read sequencing that the genome assembly is difficult and prone to errors, can more accurately locate the genome repetitive sequences, and more accurately identify large SVs. BRIEF DESCRIPTION OF THE DRAWINGS

[0037] Figure 1 Schematic diagram of the detection system of the present invention.

[0038] Figure 2 This is the ONT long-read sequencing test result for a sample using the kit in Example 2.

[0039] Figure 3 This is the ONT long-read sequencing test result of another sample using the kit of Example 2. DETAILED DESCRIPTION

[0040] The present invention will be further described below in conjunction with specific embodiments. It should be understood that these embodiments are only used to illustrate the present invention and are not intended to limit the scope of the present invention. In addition, it should be understood that after reading the content taught by the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms fall within the scope limited by the appended claims of the application equally.

[0041] In the present application, the term "leukemia" generally refers to a disease caused by the massive proliferation and accumulation of leukemia cells, which usually starts in the bone marrow. The leukemia may include B-cell acute lymphoblastic leukemia and / or T-cell acute lymphoblastic leukemia.

[0042] In this application, the term "subject" generally refers to an individual with a certain disease manifestation, which can refer to the symptoms of the disease or to a harmful physiological state that cannot be changed in a preventive situation. The individual can include males and / or females, and generally includes humans or non-human animals, such as non-human mammals. In certain embodiments, the individual includes, but is not limited to, humans, dogs, cats, horses, sheep, goats, pigs, cattle, rabbits, rats, mice, monkeys, etc. For example, the subject can be a human patient.

[0043] In the present application, the term "sample" generally refers to a sample for the sample unit that can be taken directly or indirectly from a subject and from which a leukemia cell suspension can be obtained. In certain embodiments, the sample taken directly from the subject is not further processed, for example, blood can be obtained from the peripheral circulatory system of the subject (for example, through a blood collection needle). The sample may include, for example, blood, urine, feces, saliva, cerebrospinal fluid, sweat, etc. Non-limiting examples of such samples include blood (or components of blood - e.g., white blood cells, red blood cells, platelets) obtained from any anatomical location of a subject (e.g., tissue, circulatory system, bone marrow), cells obtained from any anatomical location of a subject, skin, heart, lung, kidney, exhaled breath, bone marrow, stool, semen, vaginal fluid, tissue fluid from tumor tissue, breast, pancreas, cerebrospinal fluid, tissue, throat swab, biopsy, placental fluid, amniotic fluid, liver, muscle, smooth muscle, bladder, gall bladder, colon, intestine, brain, cavity fluid, sputum, pus, micropiota, meconium, breast milk, prostate, esophagus, thyroid, serum, saliva, urine, gastric and digestive fluids, tears, ocular fluids, sweat, mucus, cerumen, oils, glandular secretions, spinal fluid, hair, nails, skin cells, plasma, nasal swab or nasopharyngeal wash, spinal fluid, umbilical cord blood, lymph and / or other excreta or body tissues. In certain embodiments, the sample is a bone marrow sample derived from a subject, for example, it contains bone marrow cells and / or blood cells of the subject. For another example, the sample is a bone marrow sample of a leukemia patient, wherein leukemia cells account for more than 90%.

[0044] In this application, the term "suspension" generally refers to a cell suspension formed by one or more cells dispersed in a liquid, wherein the cells can be separated as individuals or in clumps consisting of no more than about 50, no more than about 40, no more than about 30, no more than about 20, no more than about 10 or fewer cells.

[0045] In the present application, the term "leukemia cell" generally refers to an immature white blood cell produced by the pathological differentiation of hematopoietic stem cells. For example, leukemia cells generally do not have the functions of normal cells, but may also have a strong proliferation ability.

[0046] In the present application, the term "cell density" or "density" generally refers to the number of cells contained in a unit volume in a cell suspension. In the present application, a cell suspension can be obtained by using a culture medium, as long as the culture medium can make the cells grow normally. In some embodiments, the culture medium also makes the cells in a suspended state. For example, RPMI cell culture medium can be used to prepare a leukemia cell suspension. For another example, DMEM culture medium, IMDM culture medium, HAMF12 culture medium, MEM culture medium, 199 cell culture medium, MDSS2 cell culture medium, etc. can be used.

[0047] Example 1

[0048] Depend on Figure 1 As shown, this embodiment provides a molecular typing detection system based on third-generation sequencing, including:

[0049] a) Sample module;

[0050] The sample modules include:

[0051] a1) a sample unit comprising a leukemia cell suspension derived from a subject, wherein the density of the leukemia cells in the suspension is 2×10 7 / ml to 5x10 7 / ml;

[0052] b) at least one detection module, which is used to detect leukemia cells and structural variations present in the subject, so as to perform molecular typing;

[0053] The at least one detection module comprises:

[0054] b1) an extraction unit, which contains reagents that can easily extract DNA to obtain DNA for subsequent detection;

[0055] The reagents include lysis solution, enzyme inhibitors, buffer and distilled water.

[0056] Furthermore, the sample module also includes:

[0057] a2) a separation unit, comprising a monocyte separation solution for centrifugally separating the leukemia cells of the subject.

[0058] a3) A T cell depletion unit, which is used to deplete T cells from a sample derived from a subject with non-T cell leukemia, thereby obtaining the leukemia cell suspension.

[0059] Furthermore, the detection module also includes:

[0060] b2) A data analysis unit, which includes a module for analyzing the sequencing results to obtain characteristic gene sequences of the subject's leukemia cells.

[0061] b3) A molecular typing unit, which comprises the characteristic gene sequence of the leukemia cells of the above-mentioned subject, thereby obtaining the SV type of the leukemia cells of the subject.

[0062] Example 2

[0063] This embodiment provides a molecular typing detection kit based on third-generation sequencing, including a DNA extraction reagent; the DNA extraction reagent includes a lysate, an enzyme inhibitor, a buffer and distilled water. The lysate includes buffer AL, buffer MB, buffer MW1, buffer PE, buffer AE and MagAttract Suspension G. The enzyme inhibitor includes proteinase K and RNase A. The buffer is a PBS buffer.

[0064] This embodiment also provides a specific method for using the above-mentioned third-generation sequencing-based molecular typing detection kit, comprising the following steps:

[0065] 1. Obtaining HMW DNA from samples

[0066] 1. When an acute lymphoblastic leukemia patient is initially diagnosed by immunophenotype and cell morphology, a sample (eg, a blood cell sample, or a DNA sample extracted from the cell) is obtained from the subject.

[0067] 2. For each subject, about 2 ml of bone marrow sample was collected each time (the proportion of leukemia cells in the bone marrow sample was at least 90%). 5 ml of cell suspension of the sample was prepared in culture medium and density gradient centrifugation was performed using Ficoll. During this process, 5 ml of Ficoll lymphocyte separation solution was injected into the lower layer of the cell suspension and centrifuged at 800g for 30 minutes at room temperature. After centrifugation, the cells in the middle layer were carefully collected and transferred to RPMI cell culture medium to obtain a leukemia cell suspension derived from the subject.

[0068] 3. After that, the leukemia cell suspension was centrifuged at room temperature and 300g for 8 minutes. The precipitated cells were washed with RPMI cell culture medium and centrifuged at room temperature and 300g for 8 minutes, and the supernatant was removed. The obtained cells were suspended in fetal bovine serum containing about 10% DMSO and prepared into a cell suspension with a cell density of about 2x107 / ml to about 5x107 / ml. Cells that were not to be used immediately were frozen and stored in liquid nitrogen.

[0069] 4. Take 1x107 cells from the patient and resuspend them in 200ul PBS.

[0070] 5. Use MagAttract HMW DNA kit to separate the DNA in the cell suspension to obtain the DNA of the subject.

[0071] 6. Add 20ul Proteinase K to a 2ml centrifuge tube and add 200ul PBS to resuspend the cell sample.

[0072] 7. Add 4ul RNase A and 150ul buffer AL, mix thoroughly, and incubate at room temperature for 30min.

[0073] 8. Add 15ul MagAttract Suspension G to the above mixture.

[0074] 9. Add 280ul Buffer MB and mix thoroughly. Incubate at room temperature at 1400rpm for 3min.

[0075] 10. Place the centrifuge tube on the magnetic rack, remove the supernatant after the solution is clarified, add 700ul buffer MW1, and incubate at 1400rpm for 1min at room temperature. Repeat this operation once.

[0076] 11. Place the centrifuge tube on the magnetic rack, remove the supernatant after the solution is clarified, add 700ul buffer PE, and incubate at room temperature at 1400rpm for 1min. Repeat this operation once.

[0077] 12. Place the centrifuge tube on the magnetic rack, remove the supernatant after the solution is clarified, add 700ul distilled water, and incubate on the magnetic rack at room temperature for 1min. Repeat this operation once.

[0078] 13. Place the centrifuge tube on the magnetic rack, remove the supernatant after the solution becomes clear, and add 100ul buffer AE to resuspend the magnetic beads.

[0079] 14. Incubate at 1400 rpm for 1 min at room temperature.

[0080] 15. Place the centrifuge tube on the magnetic rack and wait for the solution to become clear before collecting the supernatant, which is the DNA solution.

[0081] 16. Dilute the DNA samples obtained from the subjects, with the target concentration not less than 50ng / ul and the volume not less than 100ul. 2. Detection of leukemia structural variation (SV) using third-generation sequencing molecular typing

[0082] The DNA obtained in step 1 was adjusted to >50 ng / ul according to the concentration of Nanodrop. Then, the library was built according to the ONT PromethION library construction process, and the data analysis after sequencing on the machine could obtain the specific leukemia SV diagnosis.

[0083] 3. Specifically, 8 samples of different subtypes of B-ALL that have been verified by next-generation sequencing were selected, including 1 case of TCF3-PBX1 rearrangement, 3 cases of BCR-ABL / -like, 1 case of KMT2A-AFF1 rearrangement, 1 case of PAX5 rearrangement, and 2 cases of B-other subtype. DNA was extracted from these samples, and the library was constructed according to the ONT library construction process to obtain sequencing data.

[0084] ONT sequencing was used to compare the accuracy of molecular typing with that of clinical second-generation sequencing. Three-generation sequencing was performed on six B-ALL samples with confirmed molecular typing. The test results are shown in the following table.

[0085] Table 1 Breakpoints of sample rearrangements detected by ONT long-read sequencing

[0086] sample Rearrangement Type chromosome 1 Location chromosome 2 Location RJ-3 TCF3-PBX1 chr1 164792665 chr19 1617929 RJ-5 BCR-ABL chr9 130778953 chr22 23222153 RJ-6 BCR-ABL chr9 130778953 chr22 23222154 RJ-10 ZC3HAV1-ABL2 chr1 179142139 chr7 139051102 RJ-4 KMT2A-AFF1 chr4 87071489 chr11 118484048 RJ-8 PAX5-ETV6 chr9 37002649 chr12 11824931

[0087] For the above 6 B-ALL patients who have been clinically diagnosed, ONT sequencing can detect all driver genes with an accuracy rate of 100% (6 / 6).

[0088] For B-other patients, no SVs related to leukemia typing were detected clinically, but a large number of SVs were detected using ONT sequencing. Figure 1 (RJ-19) and Figure 2 (RJ-20) Although according to the current molecular typing standards, B-other has no leukemia-related SVs, the ONT long-read sequencing results showed that there were a large number of SVs in B-other samples.

Claims

1. A molecular typing detection system based on third-generation sequencing, comprising: a) Sample module; The sample modules include: a1) a sample unit comprising a leukemia cell suspension derived from a subject, wherein the density of the leukemia cells in the suspension is 2×10 7 / ml to 5x10 7 / ml; b) at least one detection module, which is used to detect leukemia cells and structural variations present in the subject, so as to perform molecular typing; Wherein the at least one detection module comprises: b1) an extraction unit, which contains reagents that can easily extract DNA to obtain DNA for subsequent detection; The reagents include lysis solution, enzyme inhibitors, buffer and distilled water.

2. A molecular typing detection system based on third-generation sequencing according to claim 1, characterized in that: The sample module further comprises a2) a separation unit, wherein the separation unit comprises a monocyte separation solution for centrifugally separating the leukemia cells of the subject.

3. A molecular typing detection system based on third-generation sequencing according to claim 1, characterized in that: The sample module further comprises a3) a T cell removal unit for removing T cells from a sample derived from a non-T cell leukemia subject, thereby obtaining the leukemia cell suspension.

4. A molecular typing detection system based on third-generation sequencing according to claim 1, characterized in that: The detection module also includes b2) a data analysis unit, which is used to analyze the sequencing results to obtain the characteristic gene sequence of the subject's leukemia cells.

5. A molecular typing detection system based on third-generation sequencing according to claim 1, characterized in that: The detection module also includes b3) a molecular typing unit, which contains the characteristic gene sequence of the leukemia cells of the above-mentioned subject, so as to obtain the SV type of the leukemia cells of the subject.

6. A molecular typing detection system based on third-generation sequencing according to claim 1, characterized in that: The detection module includes 2 or more detection modules, at least one of which is used to detect the presence and / or proportion of leukemia cells in the subject before the subject receives the treatment, and at least one of which is used to detect the presence and / or proportion of leukemia cells in the subject after the subject receives the treatment.

7. A molecular typing detection kit based on third-generation sequencing, characterized in that: The method comprises a DNA extraction reagent, wherein the DNA extraction reagent comprises a lysate, an enzyme inhibitor, a buffer solution and distilled water.

8. A molecular typing detection kit based on third-generation sequencing according to claim 7, characterized in that: The lysis solution includes buffer AL, buffer MB, buffer MW1, buffer PE, buffer AE and MagAttractSuspension G.

9. A molecular typing detection kit based on third-generation sequencing according to claim 7, characterized in that: The enzyme inhibitors include proteinase K and RNase A.

10. A molecular typing detection kit based on third-generation sequencing according to claim 7, characterized in that: The sample DNA is extracted using the DNA extraction reagent and then a library is constructed. After sequencing on a machine, the molecular typing result of leukemia is obtained through data analysis.

Citation Information

Patent Citations

  • Primer and probe for real-time fluorescence PCR (polymerase chain reaction) detection of goose down component

    CN104630345A

  • System for leukemia diagnosis and treatment

    CN108937848A

  • High-throughput single-cell transcriptome and gene mutation integration analysis method

    CN110577983A

  • Kit for directly detecting methylation of BCR-ABL1 fusion gene promoters in multiple samples and use method

    CN115961008A